VLP-102

VLP-102 is an investigational immunotherapy consisting of a single-cycle alphavirus replicon particle (VRP) vector that encapsulates self-amplifying RNA (saRNA) encoding interleukin-12 (IL-12). Developed by VLP Therapeutics, the platform leverages the natural tropism of alphaviruses for myeloid cells, such as tumor-associated macrophages (TAMs) and neutrophils (TANs), to deliver the IL-12 transgene directly into the tumor microenvironment. The VRP is engineered with a specific mutation in the capsid nuclear localization signal to enhance transgene expression while minimizing host cell toxicity. Upon intratumoral administration, the saRNA drives local production of IL-12, which reprograms immunosuppressive myeloid cells toward pro-inflammatory phenotypes, activates cytotoxic NK and T cells, and induces systemic anti-tumor immunity. VLP-102 is currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors.

Other names

interleukin-12 virus replicon particleinterleukin12 virus replicon particleinterleukin 12 virus replicon particlealphavirus replicon expressing IL-12IL-12 VRPIL12 VRPIL 12 VRP